Lipocine Inc — Cash Flow (NASDAQ:LPCN) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -15.3 M-4.41 M-11.97 M-11.87 M-1.22 M-9.76 M -9.76 M Cash from investing activities 3.89 M-43.78 M14.29 M13.08 M2.45 M5.89 M 5.89 M Cash from financing activities 20.9 M26.92 M-2.13 M404.57 K209.34 K2.87 M 2.87 M Free cash flow -15.3 M-4.42 M-12.1 M-11.88 M-1.31 M-9.76 M -9.76 M

News

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.13%

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates

Lipocine completes patient visits in phase 3 trial for PPD treatment

H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress

Lipocine completes enrollment in phase 3 trial for PPD treatment

Lipocine’s PPD drug trial continues after positive safety review

Lipocine reaches 80% enrollment in postpartum depression drug trial

Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting

Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline

Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates

Lipocine reports one-third enrollment in PPD treatment trial